Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Has announcements × Emapalumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphohistiocytosis, Hemophagocytic 1

Interventions

umbralisib 1 ublituximab 1 relatlimab 1 pembrolizumab 1 palbociclib 1 inavolisib 1 imetelstat 1 Pemetrexed 1 Nivolumab 1 GRN163L peptide 1 Fulvestrant 1 Emapalumab 1 Cisplatin 1 Bendamustine Hydrochloride 1 ALT-803 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01818492 2023-02-21

Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis

Swedish Orphan Biovitrum

Phase 2/3 Completed

45 enrolled 20 charts 1 FDA

Lymphohistiocytosis, Hemophagocytic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡